Clinical trials: Post COVID Condition
COVID-19 Pandemic
Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity
A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of…
- Trial name
- COVID-19 (NCT05239832)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Postural Orthostatic Tachycardia Syndrome
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic…
- Trial name
- POTS (NCT05633407)
- Testing
- Efgartigimod
- Where
- 11 sites in United States
- Volunteers
- 53 people
- Sponsor
- argenx
COVID-19, Diabetes Mellitus
Incidence of Diabetes After a COVID-19 Infection
Prospective observational study of the POINTED consortium to evaluate whether new diagnoses of diabetes mellitus, occur significantly more frequently in the post-acute phase of a laboratory-confirmed SARS-CoV-2 infection than in…
- Trial name
- POINTED_Diab (NCT05524792)
- Testing
- no interventional study
- Where
- Germany
- Volunteers
- 157,134 people
- Sponsor
- InGef - Institute for Applied Health Research Berlin GmbH
Long COVID
A Study to Assess Anktiva in Patients With Long Covid-19.
This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
- Trial name
- INTERRUPT_LC (NCT07108036)
- Testing
- N-803 (IL-15 Superagonist)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- ImmunityBio, Inc.
Respiratory Disease, Asthma
Digital App for Telerehabilitation in Respiratory Diseases
The purpose of this study is to evaluate the feasibility and the mid-term effects of a pulmonary rehabilitation intervention, delivered by digital App, on quality of life of patients affected by respiratory diseases.
- Conditions
- Respiratory Disease, Asthma, Long COVID, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05572346
- Testing
- Home-based telerehabilitation program delivered through digital devices
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- MedicAir Healthcare S.r.l.
COVID-19 Pandemic
Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine
A Randomized, Double Blind, Positive Control Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18…
- Trial name
- COVID-19 (NCT05238649)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg, Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg, SARS-Cov-2 Vaccine Inactivated
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
URTI, Bronchiolitis
Assessement of Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms
The purpose of this post-market clinical investigation is to assess in a real-life setting, the effectiveness, usage, tolerance, safety and satisfaction of 4 isotonic and hypertonic seawater-based CE-marked nasal sprays.
- Conditions
- URTI, Bronchiolitis, COVID - 19, Allergic Rhinitis
- Trial name
- SeaBridge (NCT07262450)
- Testing
- Respimer® Hygiene-Prevention -Baby, kids, adults, Respimer® Hygiene-Prevention Kids, adults, Respimer® Decongestion Baby, kids, adults
- Where
- 32 sites in France
- Volunteers
- 1,065 people
- Sponsor
- Laboratoire de la Mer
Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19)
A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir
Healthy adults will be enrolled into this open-label, Phase 1 research study. Participants will spend about 9 nights and 10 days in the clinical research unit (CRU) and the total time in the study will be about 11 weeks.
- Conditions
- Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), COVID-19 (Coronavirus Disease 2019), Upper Respiratory Tract Infections
- Trial name
- NCT07552779
- Testing
- Ibuzatrelvir co-process API film coated tablet, Ibuzatrelvir filmcoated tablet
- Where
- Belgium
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
Long COVID
Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.
There are approximately 12 million Americans with COVID-19 Long Hauler Symptoms, including athletes. The symptoms include hypoxemia (low SaO2), fatigue, coughing/sneezing, dyspnea, trouble breathing, body aches, headaches.
- Trial name
- NCT04871815
- Testing
- sodium pyruvate nasal spray
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Cellular Sciences, inc.
Long Covid, Depression
Development of an Accessible Cognitive Behavioral Therapy Digital Therapeutic for Individuals With Long COVID
This study will evaluate Toivoa-004 as an experimental digital therapeutic for persons with Long COVID suffering from anxiety or depression.
- Conditions
- Long Covid, Depression, Anxiety
- Trial name
- NCT07714889
- Testing
- Rauha® Digital Therapeutic Platform (Toivoa-004)
- Sponsor
- Toivoa Inc
Respiratory Viral Infection, Respiratory Tract Diseases
PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)
This is an open label controlled household-randomised trial designed to evaluate the efficacy of RESP301 alongside standard of care ("SOC") versus SOC alone.
- Conditions
- Respiratory Viral Infection, Respiratory Tract Diseases, COVID-19 Respiratory Infection
- Trial name
- PREVENT (NCT04842331)
- Testing
- RESP301 (a nitric oxide generating solution), Standard of Care (SOC)
- Where
- United Kingdom
- Sponsor
- Thirty Respiratory Limited
Cognitive Decline, Cognitive Dysfunction
Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients
The objective of this study is to compare the impact of the coronavirus disease (SARS-CoV-2, or COVID-19) on cognitive function in the population of patients who have been diagnosed, treated and recovered from the COVID-19…
- Conditions
- Cognitive Decline, Cognitive Dysfunction, Brain Health, Post CoV-2 Syndrome
- Trial name
- COVID19 (NCT04950673)
- Testing
- Cognivue
- Where
- 4 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cognivue, Inc.
COVID-19 Infection
Extension Study in a Cohort of Adult Patients With COVID-19 Infection
The main objective of this study is to evaluate the incidence of post-COVID morbidity and characterize the complications profile in patients who participated in the APLICOV-PC study.
- Trial name
- E-APLICOV-PC (NCT05121740)
- Testing
- Plitidepsin 1.5 mg / day, Plitidepsin 2.0 mg / day, Plitidepsin 2.5 mg / day
- Where
- 10 sites in Spain
- Volunteers
- 34 people
- Sponsor
- PharmaMar
COVID-19 Vaccination
Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)
This study is to identify any problems and questions with respect to the safety of Comirnaty Injection (Bretovameran) during the post-marketing period.
- Trial name
- NCT06613984
- Testing
- Bretovameran
- Where
- South Korea
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Pfizer
Post-acute COVID-19 Syndrome
SENSING-AI Cohort for Long COVID Patients
The prospective study will focus on the collection of biometric and psychometric data from a limited population for 1 month with the aim of complementing the SENSING-AI retrospective cohort.
- Trial name
- SENSING-AI (NCT05204615)
- Testing
- Collection of clinical, psychometric and biometric data
- Where
- 2 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Adhera Health, Inc.
Long COVID, Post-COVID-19 Condition
A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition
REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.
- Conditions
- Long COVID, Post-COVID-19 Condition, Post-COVID Syndrome, Post-COVID Condition
- Trial name
- NCT07184385
- Testing
- REGENECYTE
- Volunteers
- 60 people
- Sponsor
- StemCyte, Inc.
Post-COVID-19 Syndrome, Fatigue Syndrome, Chronic
REGAIN: RCT of Oxaloacetate for Fatigue in Long COVID
Following acute COVID-19, some patients develop a group of debilitating symptoms that include fatigue, orthostatic intolerance, difficulty with attention and concentration (often called "brain fog"), myalgias and disrupted sleep.
- Trial name
- NCT05840237
- Testing
- Anhydrous Enol-Oxaloacetate, a "Medical Food", White Rice Flour
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Terra Biological LLC
SARS-CoV-2 Infection, Fibrosis Lung
Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia
The innovative drug Treamid is planned for use in the rehabilitation of patients after COVID-19 pneumonia in a pilot, multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to assess the efficacy and…
- Trial name
- NCT04527354
- Testing
- Treamid
- Where
- 8 sites in Russia
- Volunteers
- 60 people
- Sponsor
- PHARMENTERPRISES LLC
SARS-CoV-2 Acute Respiratory Disease
Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population
The COVID-19 pandemic caused by SARS-CoV-2 since December 2019 has caused more than 210 million cases worldwide as of September 1, 2021.
- Trial name
- COVCAL (NCT05135585)
- Testing
- Blood sample collection, Questionnaires
- Where
- 3 sites in New Caledonia
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
COVID-19
Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV
Study objectives: To evaluate the immunogenicity and immunity persistence and safety of recombinant novel coronavirus vaccine (CHO cells) after booster immunization in populations vaccinated with two doses of marketed novel…
- Trial name
- NCT05205083
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.